Evidence map›Paper›PMID 33411732›Full record

Trial reportPloS one2021

Personality dimensions of patients can change during the course of parkinson's disease.

Mathilde Boussac, Christophe Arbus, Julia Dupouy, Estelle Harroch, Vanessa Rousseau, Aurélie Croiset, Fabienne Ory-Magne, Olivier Rascol, Caroline Moreau, Anne-Sophie Rolland and 19 more

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06008704 (Pathophysiology of Pain in Parkinson's Disease), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06008704 narecruitingnot on this mapstarted 2024, after this paper: background citation

Pathophysiology of Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)

TypeinterventionalSponsorUniversity Hospital, ToulouseRan2024 to 2026Enrolled34ConditionsParkinson DiseaseArmsClinical assessment, Pain characteristics assessment, MRI, Thermotest, UPDRS-III Scale
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 14 institutions in 1 country.

Mathilde BoussacToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.ORCID 0000-0002-3532-6743
Christophe ArbusPsychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
Julia DupouyDepartment of Neurology, Hospital of Avignon, Avignon, France.
Estelle HarrochDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
Vanessa RousseauDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
Aurélie CroisetCERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.
Fabienne Ory-MagneToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Olivier RascolToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Caroline MoreauDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
Anne-Sophie RollandDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
David MaltêteDepartment of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
Tiphaine RouaudClinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France.
Mylène MeyerNeurology Department, Nancy University Hospital, Nancy, France.
Sophie DrapierBehavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France.
Bruno GiordanaService Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
Mathieu AnheimService de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Elodie HainqueDépartement de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
Béchir JarrayaPôle Neurosciences, Foch Hospital, Suresnes, France.
Isabelle BenatruService de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.
Nicolas AuzouCHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.
Lhaouas BelamriHôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.
Mélissa TirDepartment of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.
Ana-Raquel MarquesNeurology Department, Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France.
Stephane ThoboisUniv Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France.
Alexandre EusebioAix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
Jean Christophe CorvolDépartement de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
David DevosDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
Christine Brefel-CourbonToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
PREDI-STIM study group
Inserm · FRCentre National de la Recherche Scientifique · FRUniversité Toulouse III - Paul Sabatier · FRFrench Clinical Research Infrastructure Network · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire de Rennes · FRFondation de Rothschild · FRHôpital Laennec · FRLaboratoire de neurosciences fonctionnelles et pathologies · FRUniversité Claude Bernard Lyon 1 · FRUniversité Clermont Auvergne · FRUniversité Toulouse - Jean Jaurès · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations.

methodsAll PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations).

resultsMost personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations.

conclusionsDuring the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.

Indexed as

CharacterAgedFemaleHumansMaleMiddle AgedParkinson DiseasePersonality DisordersPersonality Inventory

Identifiers

PMID33411732
PMCPMC7790271
OpenAlexW3119453816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.